P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY

• V. Ivanov,
• S.-P. Yeh,
• J. Mayer,
• L. Saini,
• A. Unal,
• M. Boyiadzis,
• D. M. Hoffman,
• K. Kang,
• S. N. Addo,
• W. L. Mendes,
• A. T. Fathi

Affiliations

V. Ivanov

1 Almazov National Medical Research Centre, Saint Petersburg, Russia

S.-P. Yeh

2 China Medical University Hospital, Taichung City, Taiwan

J. Mayer

3 Fakultni Nemocnice Brno, Lískovec, Czechia

L. Saini

4 London Health Sciences Center, Ontario, Canada

A. Unal

5 Erciyes University Medical School, Kayseri, Turkey

M. Boyiadzis

6 Genentech Inc., South San Francisco, CA

D. M. Hoffman

7 AbbVie Inc, North Chicago, IL

K. Kang

7 AbbVie Inc, North Chicago, IL

S. N. Addo

7 AbbVie Inc, North Chicago, IL

W. L. Mendes

7 AbbVie Inc, North Chicago, IL

A. T. Fathi

8 Massachusetts General Hospital, Boston, MA, United States of America